

1 **NATIONAL INSTITUTE FOR HEALTH AND CARE**
2 **EXCELLENCE**

3 **Guideline scope**

4 **Abdominal aortic aneurysm: diagnosis and**
5 **management**

6 ***Topic***

7 The Department of Health in England has asked NICE to develop a clinical
8 guideline on abdominal aortic aneurysm.

9 This guideline will also be used to develop the NICE quality standard for
10 abdominal aortic aneurysm.

11 ***Who the guideline is for***

- 12 • People using services, families and carers and the public.
13 • Healthcare professionals in primary care.
14 • Healthcare professionals in secondary care, including:
15 – vascular specialists, including clinicians, surgeons, nurses and
16 technologists
17 – anaesthetists
18 – radiologists
19 – care of the elderly clinicians
20 – generalist clinicians and surgeons
21 – emergency care physicians.
22 • Commissioners and providers of services, including:
23 – specialist vascular services
24 – surgical services
25 – anaesthesia services
26 – radiology services
27 – emergency departments
28 – ambulance services.

29 NICE guidelines cover health and care in England. Decisions on how they
30 apply in other UK countries are made by ministers in the [Welsh Government](#),
31 [Scottish Government](#), and [Northern Ireland Executive](#).

32 ***Equality considerations***

33 NICE has carried out [an equality impact assessment](#) [add hyperlink in final
34 version] during scoping. The assessment:

- 35 • lists equality issues identified, and how they have been addressed
- 36 • explains why any groups are excluded from the scope, if this was done.

37 **1 What the guideline is about**

38 **1.1 Who is the focus?**

39 **Groups that will be covered**

- 40 • People with an increased risk of an abdominal aortic aneurysm (abdominal
41 aortic aneurysm will be defined as infrarenal aortic aneurysms, juxtarenal
42 aortic aneurysms, suprarenal aortic aneurysms and type IV
43 thoracoabdominal aneurysms, as well as aortoiliac aneurysms).
- 44 • People with a suspected or confirmed abdominal aortic aneurysm
45 (including ruptured and symptomatic unruptured).
- 46 • Specific subgroups for whom the diagnosis and management of abdominal
47 aortic aneurysm may vary and for whom subgroup or separate analyses
48 will be considered. These may include, but are not limited to:
 - 49 – women
 - 50 – people with comorbidities when the comorbidity (or management of that
51 comorbidity) may affect the diagnosis or management of an abdominal
52 aortic aneurysm, including people with other cardiovascular conditions,
53 people with obesity, people who smoke and people nearing the end of
54 life.

55 **Groups that will not be covered**

- 56 • People with type I, II, III or V thoracoabdominal aneurysms, thoracic aortic
57 aneurysms, or isolated iliac aneurysms.

58 **1.2 Settings**

59 **Settings that will be covered**

- 60 • All settings in which NHS-funded care is received.

61 **1.3 Activities, services or aspects of care**

62 **Key areas that will be covered**

- 63 1 Identifying people with abdominal aortic aneurysms:
 - 64 – signs, symptoms and risk factors that might initiate imaging for
 - 65 abdominal aortic aneurysms
 - 66 – imaging of abdominal aortic aneurysms
- 67 2 Management of asymptomatic unruptured abdominal aortic aneurysms:
 - 68 – checking for aneurysm growth and risk of rupture, including how often
 - 69 this happens and the type of imaging used
 - 70 – non-surgical interventions to reduce the rate of aneurysm growth and
 - 71 reduce the risk of rupture, including drug therapy and risk factor
 - 72 management
 - 73 – planning of surgery, taking into account aneurysm size, preoperative
 - 74 risk assessment to determine whether surgery is suitable for a person,
 - 75 preoperative imaging, interventions to reduce potential complications
 - 76 and the type of surgery used
- 77 3 Management of symptomatic unruptured abdominal aortic aneurysms
- 78 and ruptured abdominal aortic aneurysms:
 - 79 – signs, symptoms and risk factors that could indicate a ruptured
 - 80 abdominal aortic aneurysm
 - 81 – prehospital care, including permissive hypotension
 - 82 – care and investigations in the emergency department, including
 - 83 imaging
 - 84 – referral and transfer to a specialist vascular unit
 - 85 – specialist care, including emergency surgical intervention and
 - 86 perioperative management
- 87 4 Postoperative care:

- 88 – monitoring aneurysm growth or rupture in people who have had
- 89 surgery for an abdominal aortic aneurysm, including how often this
- 90 happens and the type of imaging used
- 91 – checking for complications in people who have had surgery for an
- 92 abdominal aortic aneurysm, including how often this happens and the
- 93 type of imaging used
- 94 – interventions to reduce the risk of postoperative complications in
- 95 people who have had surgery for an abdominal aortic aneurysm,
- 96 including antithrombotics
- 97 – management of postoperative complications

98 5 Service organisation:

- 99 – volume-outcome relationships in the provision of surgery

100 Note that guideline recommendations will normally fall within licensed
101 indications; exceptionally, and only if clearly supported by evidence, use
102 outside a licensed indication may be recommended. The guideline will
103 assume that prescribers will use a medicine's summary of product
104 characteristics to inform decisions made with individual patients.

105 **Areas that will not be covered**

106 1 Prevention of abdominal aortic aneurysm:

- 107 – management of risk factors for abdominal aortic aneurysm in those
- 108 without a suspected or confirmed abdominal aortic aneurysm

109 2 Identifying people with abdominal aortic aneurysm:

- 110 – population screening for abdominal aortic aneurysm

111 **1.4 Economic aspects**

112 We will take economic aspects into account when making recommendations.
113 We will develop an economic plan that states for each review question (or key
114 area in the scope) whether economic considerations are relevant, and if so
115 whether this is an area that should be prioritised for economic modelling and
116 analysis. We will review the economic evidence and carry out economic
117 analyses. The reference case used will be that for interventions with health
118 outcomes in NHS settings; therefore the preferred unit of effectiveness will be

119 the quality-adjusted life year (QALY), and costs will be considered from an
120 NHS and personal social services (PSS) perspective.

121 **1.5 Key issues and questions**

122 While writing this scope, we have identified the following key issues, and key
123 questions related to them:

- 124 1 Identifying people with abdominal aortic aneurysms:
 - 125 – Which signs, symptoms and risk factors (or combinations of these)
126 are most accurate in predicting the presence of an abdominal aortic
127 aneurysm?
 - 128 – What is the effectiveness of available risk assessment tools?
 - 129 – In addition to ultrasound, or in cases in which the aortic diameter
130 cannot be seen using ultrasound, which imaging techniques are the
131 most useful in confirming the presence of an abdominal aortic
132 aneurysm?
- 133 2 Management of unruptured abdominal aortic aneurysms:
 - 134 – What are the key comorbidities experienced by people with an
135 abdominal aortic aneurysm, and how will this affect the management
136 of their abdominal aortic aneurysm?
 - 137 – How often should people with an unruptured abdominal aortic
138 aneurysm be monitored?
 - 139 – Which imaging techniques are most useful when monitoring people
140 with an unruptured abdominal aortic aneurysm? In particular, which
141 are most useful in the assessment of the risk of rupture and the
142 suitability of the aneurysm for surgery?
 - 143 – What risk factors are associated with abdominal aortic aneurysm
144 growth and rupture?
 - 145 – Which non-surgical interventions (including drug therapy and risk
146 factor management) are effective in preventing growth and rupture in
147 people with unruptured abdominal aortic aneurysms?
 - 148 – What is the effectiveness of early surgical intervention compared with
149 a ‘watchful waiting’ approach in people with unruptured abdominal
150 aortic aneurysms?

- 151 – Which factors predict poor and good surgical outcomes in people with
152 unruptured abdominal aortic aneurysms?
- 153 – What is the effectiveness of available risk assessment tools?
- 154 – Which type of surgery is most effective in repairing unruptured
155 abdominal aortic aneurysms?
- 156 – What additional interventions (including statin therapy or the use of
157 antithrombotic drugs) are effective in improving outcomes during
158 surgery for unruptured abdominal aortic aneurysms?
- 159 **3 Management of ruptured abdominal aortic aneurysms:**
- 160 – Which signs, symptoms and risk factors (or combinations of these)
161 are most accurate in indicating the presence of a ruptured abdominal
162 aortic aneurysm?
- 163 – What is the effectiveness of available risk assessment tools?
- 164 – What interventions, such as permissive hypotension, can be used
165 before a person with a suspected ruptured abdominal aortic aneurysm
166 reaches the hospital to increase their chance of survival or improve
167 the stability of their condition?
- 168 – What interventions can be used once a person with a suspected
169 ruptured abdominal aortic aneurysm reaches the emergency
170 department to increase their chance of survival or improve the stability
171 of their condition?
- 172 – What investigations, including imaging, should the emergency
173 department use in a person with a suspected ruptured abdominal
174 aortic aneurysm?
- 175 – Which factors predict poor and good outcomes in the transfer of
176 people with ruptured abdominal aortic aneurysms, and therefore
177 indicate which people are stable enough for transfer to a specialist
178 vascular unit?
- 179 – What interventions, facilities or staffing improve outcomes in the
180 transfer of people with ruptured abdominal aortic aneurysms to a
181 specialist vascular unit?
- 182 – Which type of surgery is most effective in repairing ruptured
183 abdominal aortic aneurysms?

- 184 – What perioperative care (including type of anaesthesia, or statin
185 therapy or the use of antithrombotic drugs) is effective in improving
186 outcomes during surgical repair of ruptured abdominal aortic
187 aneurysms?
- 188 4 Postoperative care:
- 189 – How frequently should people be monitored for postoperative
190 complications, further aneurysm growth and aneurysm rupture after
191 surgical repair of an abdominal aortic aneurysm?
- 192 – When checking people after they have had surgical repair of an
193 abdominal aortic aneurysm, which imaging techniques are most
194 useful for detecting postoperative complications, further aneurysm
195 growth and aneurysm rupture?
- 196 – What interventions (including statins or antithrombotic drugs) are
197 effective in reducing the risk of complications after surgical repair of
198 an abdominal aortic aneurysm?
- 199 – How should complications, including endoleak and stent kinking or
200 migration, be managed if they do arise?
- 201 5 Service organisation:
- 202 – Do hospitals with a higher volume of surgeries per year have better
203 surgical outcomes?

204 **1.6 Main outcomes**

205 The main outcomes that will be considered when searching for and assessing
206 the evidence are:

- 207 1 Diagnostic accuracy (sensitivity, specificity, positive and negative
208 predictive values)
- 209 2 Mortality
- 210 3 Rate of aneurysm growth
- 211 4 Incidence of rupture
- 212 5 Incidence of adverse events or complications
- 213 6 Acceptability of approach to patients
- 214 7 Health-related quality of life
- 215 8 Resource use and cost

216 **2 Links with other NICE guidance and NICE** 217 **Pathways**

218 **2.1 NICE guidance**

219 **NICE guidance that will be updated by this guideline**

- 220 • [Endovascular stent–grafts for the treatment of abdominal aortic aneurysms](#)
221 (2009) NICE technology appraisal guidance 167

222 It is proposed that this guideline will update all recommendations from
223 TA167.

224 **NICE guidance about the experience of people using NHS services**

225 NICE has produced the following guidance on the experience of people using
226 the NHS. This guideline will not include additional recommendations on these
227 topics unless there are specific issues related to abdominal aortic aneurysm:

- 228 • [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- 229 • [Medicines adherence](#) (2009) NICE guideline CG76
- 230 • [Surgical site infection: prevention and treatment of surgical site infection](#)
231 (2008) NICE guideline CG74

232 **NICE guidance in development that is closely related to this guideline**

233 NICE is currently developing the following guidance that is closely related to
234 this guideline:

- 235 • [Endovascular aneurysm sealing \(EVAS\) for abdominal aortic aneurysm.](#)
236 NICE interventional procedure guidance. Publication date to be confirmed.


237 **2.2 NICE Pathways**

238 [NICE Pathways](#) bring together all related NICE guidance and associated
239 products on a topic in an interactive topic-based flow chart.

240 When this guideline is published, the recommendations will be added to a new
241 NICE pathway. Other relevant guidance will also be added to the pathway,
242 including:

- 243 • [Endovascular stent–grafts for the treatment of abdominal aortic aneurysms](#)
244 (2009) NICE technology appraisal guidance 167
- 245 • [Laparoscopic repair of abdominal aortic aneurysm](#) (2007) NICE
246 interventional procedure guidance 229
- 247 • [Stent-graft placement in abdominal aortic aneurysm](#) (2006) NICE
248 interventional procedure guidance 163
- 249 The new pathway will update and replace the existing section on abdominal
250 aortic aneurysms in the pathway on [aortic aneurysms](#).
- 251 A draft pathway outline, based on the draft scope, is included below. It will be
252 adapted and more detail added as the recommendations are written during
253 guideline development.

Abdominal aortic aneurysm overview



254

255 3 Context

256 3.1 Key facts and figures

257 Aortic aneurysms develop when the wall of the aorta weakens, causing it to
 258 bulge and form a balloon-like projection. When this weakening and expansion
 259 of the aorta occurs in the abdomen and reaches a diameter at least 1.5 times
 260 the normal diameter of the aorta, or greater than 3 cm diameter in total, the
 261 condition is known as an abdominal aortic aneurysm.

262 Further stretching of the wall of the aorta and an increase in tension may
 263 eventually lead the wall of the aneurysm to rupture. If people with a ruptured
 264 aneurysm do not quickly get emergency surgical repair, the subsequent

265 internal bleeding is fatal in approximately 80% of cases; even when they have
266 emergency surgery, only about half survive beyond 30 days. This compares
267 with a postoperative mortality rate in high-quality vascular services of around
268 2% following planned surgery.

269 Before reaching this life-threatening state there is a long period of often
270 subclinical growth in the diameter of the aneurysm, estimated at a mean of
271 2.3 mm/year in small aneurysms (those between 3.0 and 4.4 mm in diameter).
272 Symptoms that can occur as an aneurysm enlarges include a pulsating
273 sensation in the abdomen, and back and/or abdominal pain, although the
274 majority of abdominal aortic aneurysms are asymptomatic.

275 Growth and rupture rates increase significantly as the diameter of the
276 aneurysm expands. For each 0.5 cm increase in aneurysm diameter, growth
277 rates increase by about 0.5 mm/year and rupture rates double. The rate of
278 aortal growth may depend on a number of factors, including increasing age,
279 smoking, blood pressure and a family history of aneurysm.

280 Because most abdominal aortic aneurysms are asymptomatic, it is difficult to
281 estimate their prevalence; however, screening studies in the UK have
282 estimated a prevalence of between 1.3 and 12.7% depending on the age
283 group studied and the definition used. They occur most frequently in men over
284 the age of 65, amongst whom there are around 3000 deaths each year in
285 England and Wales because of rupture. Abdominal aortic aneurysms account
286 for around 1.7% of all deaths in men aged 65 and over.

287 Although the incidence of abdominal aortic aneurysms is approximately
288 6 times lower in women, the rate of aneurysm rupture is significantly higher,
289 highlighting the need for careful consideration of this population in the
290 proposed guidance.

291 **3.2 Current practice**

292 Abdominal aortic aneurysms are often asymptomatic. Self-referral for
293 assessment is therefore rare, and most diagnoses occur either through

294 targeted screening of high-risk individuals or by chance during clinical
295 investigations (for example, ultrasound or X-ray) for other conditions.

296 In 2009, the National Screening Committee began rollout of the NHS
297 Abdominal Aortic Aneurysm Screening Programme (NAAASP) for the
298 detection of abdominal aortic aneurysms in men over the age of 65, inviting
299 them for an ultrasound scan during the year they turn 65. Men over the age of
300 65 are welcome to self-refer themselves for screening as part of the NAAASP,
301 though do not receive a direct invite to do so by the scheme. Currently, the
302 programme does not offer screening to women or to men younger than 65.

303 Management of an abdominal aortic aneurysm depends primarily on its size.
304 Under the NAAASP, no further scans are planned following a normal
305 ultrasound (that is, an aortal diameter of less than 3 cm). Small and medium
306 aneurysms (that is, aortal diameters of 3.0 to 4.4 cm and 4.5 to 5.4 cm,
307 respectively) lead to conservative management. This involves regular
308 surveillance scans to check for growth of the aneurysm; for small aneurysms
309 a follow-up will be arranged in 1 year, and for medium aneurysms a follow-up
310 will be arranged in 3 months. Conservative management may also include
311 recommending lifestyle changes (such as stopping smoking, taking regular
312 exercise, losing weight or improving the diet) or medicines (such as statins,
313 aspirin or blood pressure medications) to reduce the chance of the aneurysm
314 expanding or rupturing.

315 If the aorta reaches a diameter of 5.5 cm (a large aneurysm), a patient will be
316 referred to a vascular surgeon because the risk of the aneurysm rupturing is
317 now considered to be greater than the risk of having it surgically repaired.
318 Conventional (open) surgical repair involves making a large incision in the
319 abdomen, removing the damaged section of the aorta and inserting a
320 prosthetic graft. It can also be performed laparoscopically. Alternatively,
321 endovascular aneurysm repair is a minimally invasive technique in which a
322 stent-graft is inserted through a small incision in the groin, and anchored to
323 the wall of the aorta under X-ray guidance.

324 In current UK clinical practice, the decision to have surgery and the choice of
325 surgical intervention is based on aneurysm size and morphology, patient age,
326 fitness for surgery, and the short- and long-term benefits, as well as the risks,
327 of the procedures. Potential advantages of endovascular aneurysm repair
328 over open repair include a reduced time under general anaesthesia,
329 elimination of the pain and trauma associated with major abdominal surgery, a
330 reduced length of stay in the hospital and intensive care unit, and reduced
331 blood loss. Potential disadvantages include a greater possibility that additional
332 surgery may be needed because of slipping or dislodging of the stent-graft
333 and the development of endovascular leaks (endoleaks).

334 Patients with a symptomatic aneurysm need rapid medical intervention as it
335 may be an indicator of imminent rupture. In these cases, and in particular
336 when rupture occurs, emergency surgical repair may be needed. The use of
337 endovascular aneurysm repair is not currently recommended in the treatment
338 of ruptured abdominal aortic aneurysms.

339 After either elective or emergency surgery, follow-up checks and management
340 - including both lifestyle and medical management - are important in ensuring
341 that further aneurysm growth or risk of rupture is minimised.

342 **3.3 Policy, legislation, regulation and commissioning**

343 NHS Abdominal Aortic Aneurysm Screening Programme (2011) Essential
344 elements in developing an abdominal aortic aneurysm (AAA) screening and
345 surveillance programme

346 NHS Commissioning Board (2013) Clinical Commissioning Policy: Complex
347 Endovascular Stent Grafts in Abdominal Aortic Aneurysm

348 NHS England (2013) A04/S/a 2013/14 NHS Standard contract for specialised
349 vascular services (adults)

350 Public Health England (2013) Cross-border operational protocol: NHS
351 Abdominal Aortic Aneurysm Screening Programme and Wales Abdominal
352 Aortic Aneurysm Screening Programme

- 353 Public Health England (2014) Ultrasound equipment quality assurance
354 guidance: guidance for abdominal aortic aneurysm screening providers
- 355 Public Health England (2014) Non-visualised aortas: guidance for local AAA
356 screening programmes in the management of non-visualised screening
357 results
- 358 Public Health England (2014) NHS Abdominal Aortic Aneurysm Screening
359 Programme: guidance for monitoring of waiting times standards
- 360 Public Health England (2014) NHS public health functions agreement 2015-16
361 Service specification No.23: NHS Abdominal Aortic Aneurysm Screening
362 Programme
- 363 Public Health England (2015) Guidance for the validation of annual pathway
364 standards: abdominal aortic aneurysm screening programme
- 365 Public Health England (2015) Protocol for reporting deaths: process for AAA
366 screening programmes
- 367 Public Health England (2015) Pathway Standards for NHS Abdominal Aortic
368 Aneurysm Screening Programme
- 369 Royal College of Radiologists (2012) Best practice guidelines for the
370 management and transfer of patients with a diagnosis of ruptured abdominal
371 aortic aneurysm to a specialist vascular centre
- 372 Vascular Society (2011) Framework for improving the results of elective AAA
373 repair

374 **4 Further information**

This is the draft scope for consultation with registered stakeholders. The consultation dates are 25 August to 22 September 2015.

The guideline is expected to be published in October 2017.

You can follow progress of the guideline. [\[Hyperlink 'guideline' to its web](#)

page.]

[After consultation, delete the first paragraph above and replace it with 'This is the final scope, incorporating comments from registered stakeholders during consultation'.]

Our website has information about how [NICE guidelines](#) are developed.

375